Historical Valuation
Gossamer Bio Inc (GOSS) is now in the Fair zone, suggesting that its current forward PS ratio of 28.16 is considered Fairly compared with the five-year average of -2.53. The fair price of Gossamer Bio Inc (GOSS) is between 1.55 to 2.58 according to relative valuation methord.
Relative Value
Fair Zone
1.55-2.58
Current Price：2.50
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Gossamer Bio Inc (GOSS) has a current Price-to-Book (P/B) ratio of -8.09. Compared to its 3-year average P/B ratio of -1.49 , the current P/B ratio is approximately 442.92% higher. Relative to its 5-year average P/B ratio of -1.12, the current P/B ratio is about 621.69% higher. Gossamer Bio Inc (GOSS) has a Forward Free Cash Flow (FCF) yield of approximately -23.78%. Compared to its 3-year average FCF yield of -57.85%, the current FCF yield is approximately -58.90% lower. Relative to its 5-year average FCF yield of -45.75% , the current FCF yield is about -48.03% lower.
P/B
Median3y
-1.49
Median5y
-1.12
FCF Yield
Median3y
-57.85
Median5y
-45.75
Competitors Valuation Multiple
AI Analysis for GOSS
The average P/S ratio for GOSS competitors is 36.30, providing a benchmark for relative valuation. Gossamer Bio Inc Corp (GOSS.O) exhibits a P/S ratio of 28.16, which is -22.41% above the industry average. Given its robust revenue growth of 40.23%, this premium appears sustainable.
Performance Decomposition
AI Analysis for GOSS
1Y
3Y
5Y
Market capitalization of GOSS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of GOSS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is GOSS currently overvalued or undervalued?
Gossamer Bio Inc (GOSS) is now in the Fair zone, suggesting that its current forward PS ratio of 28.16 is considered Fairly compared with the five-year average of -2.53. The fair price of Gossamer Bio Inc (GOSS) is between 1.55 to 2.58 according to relative valuation methord.
What is Gossamer Bio Inc (GOSS) fair value?
GOSS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Gossamer Bio Inc (GOSS) is between 1.55 to 2.58 according to relative valuation methord.
How does GOSS's valuation metrics compare to the industry average?
The average P/S ratio for GOSS's competitors is 36.30, providing a benchmark for relative valuation. Gossamer Bio Inc Corp (GOSS) exhibits a P/S ratio of 28.16, which is -22.41% above the industry average. Given its robust revenue growth of 40.23%, this premium appears sustainable.
What is the current P/B ratio for Gossamer Bio Inc (GOSS) as of Jan 10 2026?
As of Jan 10 2026, Gossamer Bio Inc (GOSS) has a P/B ratio of -8.09. This indicates that the market values GOSS at -8.09 times its book value.
What is the current FCF Yield for Gossamer Bio Inc (GOSS) as of Jan 10 2026?
As of Jan 10 2026, Gossamer Bio Inc (GOSS) has a FCF Yield of -23.78%. This means that for every dollar of Gossamer Bio Inc’s market capitalization, the company generates -23.78 cents in free cash flow.
What is the current Forward P/E ratio for Gossamer Bio Inc (GOSS) as of Jan 10 2026?
As of Jan 10 2026, Gossamer Bio Inc (GOSS) has a Forward P/E ratio of -3.95. This means the market is willing to pay $-3.95 for every dollar of Gossamer Bio Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Gossamer Bio Inc (GOSS) as of Jan 10 2026?
As of Jan 10 2026, Gossamer Bio Inc (GOSS) has a Forward P/S ratio of 28.16. This means the market is valuing GOSS at $28.16 for every dollar of expected revenue over the next 12 months.